We know that exercise is medicine. The science is clear, the mechanisms are known, and the tools are available to deliver it safely. To make all that mean something for patients, cancer care must evolve to include movement as a standard element of every stage of the journey, not as a wellness option, but as…
HarmonyCares’ Will Robinson outlines how high-needs ACOs helped CMS identify and address huge spikes in wound care spending
By MIKE MAGEE In a 1996 JAMA editorial Nobel Laureate Joshua Lederberg MD wrote “Our fight with microbes is far from over …odds are tipped in their favor…they outnumber us a billion fold, and mutate a billion times more quickly…pitted against microbial genes, we humans mainly have our wits.” Now three decades later, our scientists…
Kristin MacGregor, Ph.D., National Clinical Director for Integrated Behavioral Health at LifeStance, talks about a partnership with a large primary care medical group
The Trump administration has intervened in the release of important studies on the bird flu, as an outbreak escalates across the United States. One of the studies would reveal whether veterinarians who treat cattle have been unknowingly infected by the bird flu virus. Another report documents cases in which people carrying the virus might have…
That is according to the 2024 national health expenditure data published in Health Affairs last week (Hartman et al. 2026). Here is the abstract: Health care spending in the US reached $5.3 trillion and increased 7.2 percent in 2024, similar to growth of 7.4 percent in 2023, as increased demand for health care influenced this two-year trend. As…
Sonali Saluja, M.D., M.P.H., vice president of population health and medical director of Healthcare in Action, describes importance of data availability to mobile care teams
Approval of Syndax’s Revuforj for acute leukemia makes the twice-daily pill the first in a new class of drugs that block a cancer-driving protein called menin. Other companies developing menin inhibitors include Kura Oncology, Biomea Fusion, and Johnson & Johnson subsidiary Janssen. The post Syndax Pharmaceuticals Leukemia Drug Wins a First-in-Class FDA Approval appeared first…
Ambient clinical intelligence company is working on a prior authorization solution with Availity, which runs a real-time health information network connecting health plans and providers
Johnson & Johnson’s Imaavy is now FDA-approved for treating generalized myasthenia gravis, introducing competition to Argenx and UCB drugs that treat this rare neuromuscular disorder. J&J is also developing its new drug for other diseases and projects it could reach $5 billion in peak sales across multiple rare and prevalent conditions. The post FDA Nod…